Cyclerion Therapeutics, Inc. financial data

Symbol
CYCN on Nasdaq
Location
301 Binney Street, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 513 % +26.8%
Return On Equity -24.6 % +55.5%
Return On Assets -22.4 % +53.6%
Operating Margin -127 % +95.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.93M shares +44.8%
Common Stock, Shares, Outstanding 3.7M shares +46%
Entity Public Float 4.8M USD -32.4%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 3.23M shares +27.7%
Weighted Average Number of Shares Outstanding, Diluted 3.23M shares +27.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.86M USD +1372%
Research and Development Expense 496K USD +95.3%
General and Administrative Expense 5.99M USD +2.15%
Operating Income (Loss) -3.63M USD +38.7%
Nonoperating Income (Expense) 1.43M USD +123%
Net Income (Loss) Attributable to Parent -2.2M USD +58.4%
Earnings Per Share, Basic 0 USD/shares +58%
Earnings Per Share, Diluted 0 USD/shares +46.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.57M USD +59.1%
Accounts Receivable, after Allowance for Credit Loss, Current 100K USD +127%
Other Assets, Current 11K USD 0%
Assets, Current 5.07M USD +42.8%
Other Long-term Investments 5.35M USD 0%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 10.4M USD +17%
Accounts Payable, Current 480K USD +57.9%
Employee-related Liabilities, Current 100K USD
Liabilities, Current 877K USD +25.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -270M USD -0.82%
Stockholders' Equity Attributable to Parent 9.54M USD +16.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.54M USD +16.3%
Liabilities and Equity 10.4M USD +17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -968K USD +48.3%
Net Cash Provided by (Used in) Financing Activities 1.38M USD
Common Stock, Shares Authorized 400M shares +1900%
Common Stock, Shares, Issued 3.81M shares +40.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 407K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.57M USD +59.1%
Deferred Tax Assets, Valuation Allowance 83.2M USD +0.87%
Deferred Tax Assets, Gross 83.2M USD +0.87%
Property, Plant and Equipment, Gross 126K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 53.3M USD +9.78%
Preferred Stock, Shares Authorized 100M shares +19900%
Unrecognized Tax Benefits 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 468K USD -22.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares